4-戊氧基苯胺 | 39905-50-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-戊氧基苯胺
• 中文别名: 对戊氧基苯胺
• 英文名称: 4-pentyloxyaniline
• 英文别名: 4-pentoxyaniline
• CAS: 39905-50-5
• 化学式: C₁₁H₁₇NO
• 分子量: 179.262
• InChiKey: QZLNSNIHXKQIIS-UHFFFAOYSA-N

物化性质

• 沸点：
  311.8°C (rough estimate)
• 密度：
  0.97 g/mL at 25 °C(lit.)
• 闪点：
  >230 °F
• 稳定性/保质期：
  常规情况下不会分解，也没有任何危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xn
• 海关编码：
  2922299090
• 储存条件：
  密封保存，置于阴凉干燥处。

SDS

Name:	4-Pentyloxyaniline 99% Material Safety Data Sheet
Synonym:	Benzenamine, 4-(Pentyloxy)-
CAS:	39905-50-5

Section 1 - Chemical Product MSDS Name:4-Pentyloxyaniline 99% Material Safety Data Sheet
Synonym:Benzenamine, 4-(Pentyloxy)-

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
39905-50-5	4-Pentyloxyaniline	99%	254-695-2

Hazard Symbols: XN
Risk Phrases: 20/21

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation and in contact with skin.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. May cause cardiac disturbances. May cause methemoglobinemia, cyanosis (bluish discoloration of skin due to deficient oxygenation of the blood), convulsions, and death. The toxicological properties of this substance have not been fully investigated. May cause central nervous system depression.
Inhalation:
May cause respiratory tract irritation. May cause methemoglobinemia, cyanosis (bluish discoloration of skin due to deficient oxygenation of the blood), convulsions, tachycardia, dyspnea (labored breathing), and death. The toxicological properties of this substance have not been fully investigated. May cause cardiac abnormalities. Inhalation at high concentrations may cause CNS depression and asphixiation.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas. Containers may explode when heated.
Combustible material; may burn but does not ignite readily. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Use water spray to cool fire-exposed containers. Do NOT get water inside containers. For small fires, use dry chemical, carbon dioxide, or water spray. For large fires, use dry chemical, carbon dioxide, alcohol-resistant foam, or water spray.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed.
Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 39905-50-5: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: gold
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not applicable.
Flash Point: 109 deg C ( 228.20 deg F)
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density: .9700g/cm3
Molecular Formula: C11H17NO
Molecular Weight: 179.26

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Acids, acid chlorides, acid anhydrides, chloroformates, oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, nitrogen.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 39905-50-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Pentyloxyaniline - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2810
Packing Group: III
IMO
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2810
Packing Group: III
RID/ADR
Shipping Name: TOXIC LIQUID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2810
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21 Harmful by inhalation and in contact with
skin.
Safety Phrases:
S 23 Do not inhale gas/fumes/vapour/spray.
WGK (Water Danger/Protection)
CAS# 39905-50-5: No information available.
Canada
CAS# 39905-50-5 is listed on Canada's NDSL List.
CAS# 39905-50-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 39905-50-5 is listed on the TSCA inventory.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-戊氧基苯胺 在 bis-triphenylphosphine-palladium(II) chloride 盐酸 、 sodium hydroxide 、 copper(l) iodide 、 三乙胺 、 potassium iodide 、 sodium nitrite 作用下， 以 甲醇 为溶剂， 生成 4-乙炔基苯戊醚
  参考文献：
  名称：

  向列溶剂中非极性和极性溶质的排序

  摘要：

  通过核磁共振 (NMR) 在向列溶剂己基和戊氧基取代的二苯基联乙炔 (DPDA- C6 和 DPDA-OC5，分别）。对非极性 (DPDA-C6) 和极性 (DPDA-OC5) 溶剂以及整个向列型溶剂中标称非极性 (1,4-DCB) 和极性 (1,2-DCB) 溶质的所有四种组合进行测量溶液的温度范围。从这些测量中获得了溶质的二级取向有序参数的温度依赖性，并且溶剂分子的介晶核的相应有序参数独立于碳 13 NMR 测量获得。发现两种溶质的顺序参数分布非常不同，但从一种溶剂到另一种溶剂几乎没有变化。使用 atomist 根据潜在的分子相互作用对结果进行分析和解释...

  DOI：

  10.1063/1.1560941
• 作为产物：
  描述：

  对乙酰氨基酚 在 水 作用下， 生成 4-戊氧基苯胺
  参考文献：
  名称：

  Novel calamitic side-chain metallomesogenic polymers with ferrocene in the backbone: synthesis and properties of thermotropic liquid-crystalline poly(ferrocenylsilanes)

  摘要：

  制备出了主链为聚（二茂铁硅烷）、侧链为 4-戊氧基-4′-羟基己氧基偶氮苯或 4-戊氧基-4′-羟基十一烷氧基偶氮苯丙烯酸酯的新型热致金属聚合物；每种材料都呈现出向列介相。

  DOI：

  10.1039/a607238k

文献信息

• Reaction of substituted 1-methylthio-4,5-dihydro[1,2]dithiolo[3,4-c]quinolin iodides with arylamines. Synthesis of novel 1,2-dithiolo[3,4-c]quinolin-1-ylidene(aryl)amines and 10-(arylimino)-7,10-dihydro[1,2]dithiolo[3,4-c]pyrrolo[3,2,1-ij]quinoline-4,5-diones
  作者：Svetlana M. Medvedeva、Fedor I. Zubkov、Kristina Yu. Yankina、Dmitry G. Grudinin、Khidmet S. Shikhaliev

  DOI：10.24820/ark.5550190.p010.140

  日期：——

  series of novel (8-R-7-R’-4,4-dimethyl-4,5-dihydro-1H-[1,2]dithiolo[3,4-c]quinolin-1-ylidene)(4(2)-R”phenyl)amines were synthesized by reaction of 4,4-dimethyl-1-methylthio-4,5-dihydro[1,2]dithiolo[3,4c]quinolin iodides with arylamines in an efficient manner. The Stolle type reaction of the obtained compounds with oxalyl chloride gave 2-R-3-R’-10-[(4(2)-R”-phenyl)imino]-7,7-dimethyl-7,10-dihydro[1,2]dithiolo[3

  一系列新型(8-R-7-R'-4,4-二甲基-4,5-二氢-1H-[1,2]二硫醇[3,4-c]喹啉-1-亚基)(4( 2)-R”苯基)胺是通过4,4-二甲基-1-甲硫基-4,5-二氢[1,2]二硫醇[3,4c]喹啉碘化物与芳基胺以有效方式反应合成的。所得化合物与草酰氯的 Stolle 型反应得到 2-R-3-R'-10-[(4(2)-R”-苯基)亚氨基]-7,7-二甲基-7,10-二氢[ 1,2]dithiolo[3,4c]pyrrolo[3,2,1-ij]quinoline-4,5-diones。合成化合物的结构通过核磁共振谱、质谱和元素分析表征。
• Ethanesulfonamide derivatives
  申请人：Ortho Pharmaceutical Corporation

  公开号：US05112866A1

  公开（公告）日：1992-05-12

  The synthesis of novel ethanesulfonamide compounds is described. The novel ethanesulfonamide compounds have antisecretory activity and are used in the treatment of peptic ulcer disease. The intermediates used to prepare the ethanesulfonamides are useful in the treatment of osteoporosis and other bone wasting diseases.

  描述了新型乙烷磺酰胺化合物的合成。这些新型乙烷磺酰胺化合物具有抗分泌活性，并用于治疗消化性溃疡疾病。用于制备乙烷磺酰胺的中间体在治疗骨质疏松症和其他骨质流失疾病方面是有用的。
• [EN] SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS<br/>[FR] PYRROLO[1,2-A]PYRIMIDINES SUBSTITUÉES ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
  申请人：LYSOSOMAL THERAPEUTICS INC

  公开号：WO2016073891A1

  公开（公告）日：2016-05-12

  The invention provides substituted pyrrolo[l,2-a]pyrimi dines and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrrolo[1,2-a]pyrimidines compounds described herein include substituted 2,4-dimethyl-N-phenylpyrrolo[l,2-a]pyrimidine-8-carboxamide compounds and variants thereof.

  该发明提供了取代的吡咯并[1,2-a]嘧啶和相关的有机化合物，包含这种化合物的组合物，医疗工具包，以及使用这种化合物和组合物治疗疾病的方法，例如高雪氏病、帕金森病、路易体病、痴呆症或多系统萎缩症等。本文描述的示例取代的吡咯并[1,2-a]嘧啶化合物包括取代的2,4-二甲基-N-苯基吡咯并[1,2-a]嘧啶-8-羧酰胺化合物及其变体。
• A structure–property relationship study of bent-core mesogens with pyridine as the central unit
  作者：J. M. Marković、N. P. Trišović、T. Tóth-Katona、M. K. Milčić、A. D. Marinković、C. Zhang、A. J. Jákli、K. Fodor-Csorba

  DOI：10.1039/c3nj01430d

  日期：——

  Three series of bent-core mesogens having pyridine as the central unit have been synthesized and characterized. A series of 2,6-diaminopyridine derivatives capable of forming inter- and intramolecular hydrogen bonds exhibit very high melting points. A decrease in the polarity of the central part of the bent-core obtained by replacing the amide with ester linkages results in derivatives with lower melting

  已经合成并表征了具有吡啶作为中心单元的三个系列的弯曲核液晶元。能够形成分子间和分子内氢键的一系列2,6-二氨基吡啶衍生物表现出非常高的熔点。通过用酯键取代酰胺而获得的弯曲核的中心部分的极性降低，导致衍生物具有较低的熔点并形成B2-和B7-样中间相。连接吡啶环和内部芳环的烯基的引入有助于进一步降低五环系统中央部分的极性，并导致B1和B7相的形成。通过光学显微镜观察和差示扫描量热法（DSC）确定了相，并通过X射线研究对其进行了确认。
• Development of LM98, a Small‐Molecule TEAD Inhibitor Derived from Flufenamic Acid
  作者：Léa Mélin、Shuay Abdullayev、Ahmed Fnaiche、Victoria Vu、Narjara González Suárez、Hong Zeng、Magdalena M. Szewczyk、Fengling Li、Guillermo Senisterra、Abdellah Allali‐Hassani、Irene Chau、Aiping Dong、Simon Woo、Borhane Annabi、Levon Halabelian、Steven R. LaPlante、Masoud Vedadi、Dalia Barsyte‐Lovejoy、Vijayaratnam Santhakumar、Alexandre Gagnon

  DOI：10.1002/cmdc.202100432

  日期：2021.10.6

  demonstrating the value of this transcription factor for the development of novel anti-cancer therapies. We report herein the design, synthesis and biological evaluation of LM98, a flufenamic acid analogue. LM98 shows strong affinity to TEAD, inhibits its autopalmitoylation and reduces the YAP-TEAD transcriptional activity. Binding of LM98 to TEAD was supported by 19F-NMR studies while co-crystallization

  YAP-TEAD 转录复合物负责调节癌细胞生长和增殖的基因的表达。由于 TEAD 的过表达导致 Hippo 通路的失调已在多种癌症中得到报道。TEAD 的抑制抑制了相关基因的表达，证明了这种转录因子对于开发新型抗癌疗法的价值。我们在此报告了氟灭酸类似物 LM98 的设计、合成和生物学评价。LM98 对 TEAD 显示出很强的亲和力，抑制其自棕榈酰化并降低 YAP-TEAD 转录活性。19支持 LM98 与 TEAD 的结合F-NMR 研究同时共结晶实验证实 LM98 锚定在 TEAD 的棕榈酸袋内。LM98 降低CTGF和Cyr61的表达，抑制 MDA-MB-231 乳腺癌细胞迁移并在细胞分裂期间将细胞周期阻滞在 S 期。

表征谱图